Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil

International Journal of Geriatric Psychiatry

Volumn 13, Issue 7, 1998, Pages 445-453

  Stewart, Alan ^a,c   Phillips, Richard ^b   Dempsey, Graham ^b  

^a UNIVERSITY OF KENT   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c MEDTAP International Inc   (United Kingdom)

Author keywords

Alzheimer's disease; Cost effectiveness; Costs; Dementia; Donepezil; Markov model; Pharmaceuticals

Indexed keywords

DONEPEZIL; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HUMAN; MORTALITY; PROBABILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GREAT BRITAIN; HUMANS; INDANS; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; NOOTROPIC AGENTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031851186     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E     Document Type: Article

References (27)

1. Briggs, A., Sculpher, M. and Buxton, M. (1994) Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ. 3, 95-104.
2. Burns, A. and Förstl, H. (1996a) The Institute of Psychiatry Alzheimer's disease cohort: Part I - clinical observations. Int. J. Geriatr. Psychiat. 11, 309-320.
3. Burns, A. and Förstl, H. (1996b) The Institute of Psychiatry Alzheimer's disease cohort: Part II - clinicopathological observations. Int. J. Geriatr. Psychiat. 11, 321-327.
4. Ely, M., Brayne, C., Huppert, F. A., O'Connor, D. W. and Pollitt, P. A. (1997) Cognitive impairment: A challenge for community care. A comparison of the domiciliary service receipt of cognitively impaired and equally dependent physically impaired elderly women. Age and Ageing 26, 301-308.
5. Ely, M., Melzer, D., Brayne, C. and Opit, L. (1995) The cognitively frail elderly: Estimating population characteristics and needs of people with cognitive disability, including dementia. Report to the NHSME.
6. Ely, M., Melzer, D., Opit, L. and Brayne, C. (1996) Estimating the number and characteristics of people with cognitive disability in local populations. Res. Policy Planning14(2), 13-18.
7. Gray, A. and Fenn, P. (1993) Alzheimer's disease: The burden of illness in England. Health Trends 25(1), 31-37.
8. HM Treasury (1989) Discount rates in the public sector. Press Office, Parliament Street, London.
9. Jorm, A. F. (1990) The Epidemiology of Alzheimer's Disease and Related Disorders. Chapman and Hall, London.
10. Kavanagh, S., Schneider, J., Knapp, M., Beecham, J. and Netten, A. (1993) Elderly people with cognitive impairment: Costing possible changes in the balance of care. Health Soc. Care Commun. 1, 69-80.
11. Kavanagh, S., Scheider, J., Knapp, M., Beecham, J. and Netten, A. (1995) Elderly people with dementia: Costs effectiveness and balance of care. In The Economic Evaluation of Mental health Care (M. Knapp, Ed.). Arena, Aldershot.
12. Kay, D. W. K. and Bergman, K. (1980) Epidemiology of mental disorders among the aged in the community. In Handbook of Mental health and Aging (J. E. Birren and R. B. Sloane, Eds). Prentice-Hall, Englewood Cliffs.
13. Lubeck, D. P., Mazonson, P. D. and Bowe, T. (1994) Potential effect of tacrine on expenditures for Alzheimer's Disease. Med. Interface, October, 130-138.
14. Martin, D. C., Miller, J. K., Kapoor, W., Arena, V. C. and Boller, F. (1987) A controlled study of survival with dementia. Arch. Neurol. 44, 1122-1126.
15. Netten, A. and Dennett, J. (1997) Unit Costs of Health & Social Care. Personal Social Services Research Unit, University of Kent at Canterbury.
16. Office of Population Censuses and Surveys (OPCS) (1989a) Survey of Disability among Adults in Communal Establishments, 1986. ESRC Data Archive, Colchester.
17. Office of Population Censuses and Surveys (OPCS) (1989b) Survey of Disability among Adults in private Households, 1985. ESRC Data Archive, Colchester.
18. Rogers, S. L., Farlow, M. R., Mohr, R., Friedhoff, L. T. and the Donepezil Study Group (1998) A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50(1), 136-145.
19. Rogers, S. L., Friedhoff, L. T. and the Donepezil Study Group (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7, 293-303.
20. Sainsbury, M. J. and Lambeth, L. G. (1988) Sainsbury's Key to Psychiatry, 4th edn. Wiley, Chichester.
21. Sonnenberg, F. A. and Beck, J. R. (1993) Markov models in medical decision making: A practical guide. Med. Decision Making 13, 322-338.
22. Schneider, J., Kavanagh, S., Knapp, M., Beecham, J. and Netten, A. (1993) Elderly people with advanced cognitive impairment in England: Resource use and costs. Ageing and Soc. 13, 27-50
23. Stewart, A. (1997a) Costs of care for people with dementia aged 75 and over. Discussion Paper 1303/2, PSSRU.
24. Stewart, A. (1997b) Donepezil in the treatment of people with Alzheimer's disease: A pilot Markov approach. Discussion Paper 1324, PSSRU.
25. Stewart, A. (1997c) Pharmacotherapy in the treatment of people with Alzheimer's disease: A Markov-cycle evaluation of donepezil. Discussion Paper 1342/2, PSSRU.
26. Taylor, P. (1993) Anticholinesterase agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. McGraw-Hill, New York, pp 131-149.
27. Treeage Software Inc (1997) DATA™ 3.0.14 for Windows. Treeage Software, Williamstown, MA.